Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Coal India, UltraTech, Sun Pharma, PSU banks: Mayuresh Joshi’s stock calls
Mayuresh Joshi, Director Research, Marketsmith India, says Coal India’s weak volumes and realisations limit upside despite about 6% yield, while UltraTech’s double-digit volume outlook supports steady performance. He flags near-term demand risks for Jindal Stainless but sees long-term potential, prefers pipe plays like Welspun Corp, and remains selective on PSU banks. On Sun Pharma, he sees long-term gains but near-term execution and margin risks.
Sensex jumps 639 points, Nifty reclaims 24,100 as Reliance Industries, Sun Pharma lead rebound
BSE Sensex and NSE Nifty rebounded after three losing sessions, led by Sun Pharma, Reliance Industries and midcaps, with all sectoral indices ending higher
Organon soars 15% after India’s Sun Pharma strikes $11.8bn takeover deal - Investing.com
Organon soars 15% after India’s Sun Pharma strikes $11.8bn takeover dealInvesting.com
‘Debt Averse, Not Risk Averse’: Dilip Shanghvi on Sun Pharma’s shift to net debt for Organon deal
Addressing concerns around Organon’s muted revenue growth in recent years, Managing Director Kirti Ganorkar said there are multiple levers to drive growth across its businesses.
Sun Pharma Dividend Update: What 6.6 lakh retail holders need to know after Organon deal
At the end of the March quarter, Sun Pharma had a total of 6.6 lakh small retail shareholders, or those with an authorized share capital of up to ₹2 lakh. Starting February 2022, shareholders of Sun Pharma have received ₹62 per share as dividend payouts.
Sun Pharma a trading play on dips, banks may face difficult June quarter: Dharmesh Kant
Dharmesh Kant, Head of Research at Chola Securities, said Sun Pharma’s all-cash acquisition of Organon could improve return ratios and support valuations, but may bring overall revenue growth down to single digits. He sees a trading opportunity in Sun Pharma on price dips. On banking, he said Q1 could be difficult as provisioning picks up, which may weigh on profitability even as asset quality and margins remain stable. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Market sell-off continues for 2nd day; Nifty ends below 24,200 level
Pharma and media shares advanced while auto, PSU Bank and realty shares declined.
Sun Pharma Share Price Highlights: Sun Pharma Stock Price History
Sun Pharma 'bull' explains the benefits of the potential Organon acquisition
Macquarie believes the transaction appears strategically attractive, based on the complementary nature of the two companies’ portfolios and geographic presence.
High Court relief to Sun Pharma, Ahd Co barred from using 'Esiraft'
Sun Pharmaceutical Industries has received a significant legal victory. The Bombay High Court has stopped Meghmani Lifesciences from using its product mark 'Esiraft'. This decision comes after Sun Pharma alleged trademark infringement and passing off rights concerning its brand 'Raciraft'. The court found the marks visually and phonetically similar, likely to cause confusion among consumers.
Organon shares surge 8.4% on report of Sun Pharma’s $12 billion bid - Investing.com India
Organon shares surge 8.4% on report of Sun Pharma’s $12 billion bidInvesting.com India
Explained — Why Sun Pharma shares are down 5% in a strong market
Organon has a market capitalisation of $1.5 billion. The US company specializes in women's health. It spun off from Merck Sharp & Dohme in 2021.